Search | Clinical Trials Finder

Conditions: Breast Cancer
Interventions: Doxorubicin and cyclophosphamide (AC) + bevacizumab, Docetaxel (T) + bevacizumab, Docetaxel, doxorubicin, cyclophosphamide (TAC) + bevacizumab, Docetaxel, carboplatin, trastuzumab (TCH) + bevacizumab, Bevacizumab and trastuzumab maintenance therapy, Bevacizumab maintenance therapy; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Locally Advanced or Metastatic Solid Tumor
Interventions: Rebastinib, Paclitaxel; Drug
Lead sponsor: Deciphera Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 14
States / cities: Birmingham, Alabama • Aurora, Colorado • Chicago, Illinois + 10 more

Conditions: Breast Cancer
Interventions: Ovarian Function Suppression + Aromatase Inhibitor, Adjuvant Chemotherapy + Ovarian Function Suppression; Drug
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 3,960 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2034
U.S. locations: 1226
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 809 more

Conditions: Advanced Cancer
Interventions: Nivolumab, Daratumumab; Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 5
States / cities: Long Beach, California • Aurora, Colorado • Tampa, Florida + 2 more

Conditions: Neoplasms
Interventions: MK-4830, Pembrolizumab, Carboplatin, Pemetrexed, Lenvatinib, Paclitaxel, Cisplatin, MK-4830A; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 470 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 9
States / cities: San Francisco, California • Detroit, Michigan • St Louis, Missouri + 6 more

Conditions: Estrogen Receptor-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions: Medroxyprogesterone progesterone acetate (MPA), Medroxyprogesterone with Cyclophosphamide + Methotrexate; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 7
States / cities: Birmingham, Alabama • San Francisco, California • Indianapolis, Indiana + 4 more

Conditions: Tuberculosis (TB)
Interventions: GSK's candidate Mycobacterium tuberculosis vaccine 692342; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2004
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Non-Hodgkins Lymphoma
Interventions: Rituximab; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 2
States / cities: Kansas City, Kansas

Conditions: Kita-kyushu Lung Cancer Antigen 1, Human
Interventions: IL-2 (Aldesleukin), Cyclophosphamide, KK-LC-1 TCR, Fludarabine, EKG, CXR, CT, MRI, PET, Biopsy, Acetaminophen, Ondansetron, Meperidine, Indomethacin, Famotidine; Drug · Biological · Diagnostic Test + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer
Interventions: Molecular breast imaging; Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 40 Years and older · Female only
Enrollment: 83 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Meconium Aspiration
Interventions: Lucinactant, Standard Care; Drug · Other
Lead sponsor: Windtree Therapeutics; Industry
Eligibility: Up to 48 Hours
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 1
States / cities: Warrington, Pennsylvania

Conditions: Sarcoma
Interventions: Cetuximab; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 16 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Breast Cancer, Triple Negative Breast Cancer
Interventions: Capecitabine, Talazoparib, Pembrolizumab, Inavolisib; Drug
Lead sponsor: Bryan Schneider, MD; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 13
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Hollywood, Florida + 9 more

Conditions: Complicated Intra-abdominal Infection, Hosptial Acquired Pneumonia, Ventilator Associated Pneumonia
Interventions: ATM-AVI, MTZ, MER, COL; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 422 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 5
States / cities: Tucson, Arizona • Torrance, California • Springfield, Illinois

Conditions: Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Interventions: Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21 Group 1), ficlatuzumab (BAML-16-001-S24), Azacitidine (BAML-16-001-S24), Venetoclax (BAML-16-001-S24), ZE46-0134 (BAML-16-001-S21 Group 2), Bleximenib (BAML-16-001-S25/HO181), Cytarabine (BAML-16-001-S25/HO181), Daunorubicin or Idarubicin (BAML-16-001-S25/HO181), Placebo (BAML-16-001-S25/HO181), Revumenib (BAML-16-001-S26/HO177), Placebo (BAML-16-001-S26/HO177); Biological · Other · Drug
Lead sponsor: Beat AML, LLC; Other
Eligibility: 18 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2032
U.S. locations: 31
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more

Conditions: Obstructive Sleep Apnea (OSA)
Interventions: IHL-42X: 2.5 mg dronabinol + 125 mg acetazolamide, IHL-42X: 5 mg dronabinol + 125 mg acetazolamide, IHL-42X: 7.5 mg dronabinol + 125 mg acetazolamide, IHL-42X: 2.5 mg dronabinol + 250 mg acetazolamide, IHL-42X: 5 mg dronabinol + 250 mg acetazolamide, IHL-42X: 7.5 mg dronabinol + 250 mg acetazolamide, IHL-42X: 2.5 mg dronabinol + 375 mg acetazolamide, IHL-42X: 5 mg dronabinol + 375 mg acetazolamide, IHL-42X: 7.5 mg dronabinol + 375 mg acetazolamide, Placebo: Negative control; Drug
Lead sponsor: Incannex Healthcare Ltd; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 13
States / cities: Chula Vista, California • Brandon, Florida • Jacksonville, Florida + 9 more

Conditions: Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer, Metastatic Colorectal Adenocarcinoma, Triple Negative Breast Cancer
Interventions: PF-08032562, Fulvestrant, Cetuximab, Fluorouracil, Oxaliplatin, Leucovorin, Bevacizumab; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 13
States / cities: Duarte, California • Grand Rapids, Michigan • Long Island City, New York + 7 more

Conditions: Cancer, Solid Tumor, Melanoma, Renal Cell Carcinoma, Triple-negative Breast Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Carcinoma, MSI-High
Interventions: ST-067, Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA], pembrolizumab; Biological
Lead sponsor: Simcha IL-18, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 6
States / cities: Scottsdale, Arizona • Denver, Colorado • New Haven, Connecticut + 3 more

Conditions: TNBC, TNBC - Triple-Negative Breast Cancer, Early Stage Triple-Negative Breast Carcinoma
Interventions: Ivonescimab, Carboplatin, Docetaxel; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 4
States / cities: Los Angeles, California • Pasadena, California • Torrance, California

Conditions: Healthy
Interventions: Ad26.Mos4.HIV, Clade C gp140 plus adjuvant, Clade C gp140/Mosaic gp140 plus adjuvant, Placebo, gp140 HIV Bivalent Vaccine; Biological · Other
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 11
States / cities: Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 5 more

Conditions: Breast Cancer, Early-stage Breast Cancer, High Risk Breast Carcinoma
Interventions: Abemaciclib, Tamoxifen, Anastrozole, Letrozole, Exemestane, LHRH Agonist; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 12
States / cities: Stamford, Connecticut • Brewer, Maine • Scarborough, Maine + 7 more

Conditions: Head and Neck Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma, Lung Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Skin Squamous Cell Carcinoma, Penile Squamous Cell Carcinoma
Interventions: rigosertib; Drug
Lead sponsor: Traws Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 13
States / cities: Sacramento, California • Stanford, California • Aurora, Colorado + 10 more

Conditions: Hypersensitivity
Interventions: Butenafine HCl 1% (BAY1896425), Positive Control-Sodium lauryl sulfate (SLS), Negative Control; Drug · Other
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Fairfield, New Jersey

Conditions: Triple Negative Breast Neoplasms
Interventions: Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication, Paclitaxel, Nab-paclitaxel, Gemcitabine, Carboplatin; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 39
States / cities: Mobile, Alabama • Chandler, Arizona • Duarte, California + 33 more

Search by objective public record fields.

Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer

A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread

Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)

Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer

Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine Given to PPD-Negative Adults

Evaluate Rituximab in Obtaining PCR (Polymerase Chain Reaction) Negative Leukapheresis Product in Patients With Relapsed Follicular Lymphoma

T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

Evaluation of Half-Dose Molecular Breast Imaging With Wide Beam Reconstruction Processing

Phase III Randomized Study of Lucinactant in Full Term Newborn Infants With Meconium Aspiration Syndrome

Trial of Cetuximab in Patients With Metastatic and/or Locally Advanced Soft Tissue and Bony Sarcomas

Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer

A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria.

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

DReAMzz- Dronabinol and Acetazolamide Medication for Sleep Apnea (ZZ). Dose Confirmation Crossover Study for IHL-42X in Subjects With Obstructive Sleep Apnea.

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer

A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plus Adjuvant in Healthy HIV Uninfected Adults

TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer

Oral Rigosertib for Squamous Cell Carcinoma

Study to Determine Skin Irritation Potential of an Antifungal Cream Containing Trolamine After Repeated Skin Application (Cumulative Irritation Patch Test)

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)